

From: Clegg, Patsy M SCC-CHSE-PC
Sent: Thursday, August 12, 2004 3:06 PM
To: Sullivan, Nancy E SCC-CBAR; Tholstrup, Susan C SCC-HSE; Schmid, John L SHLOIL-Legal; Clegg, Patsy M SCC-CHSE-PC
Subject: Shanghai Health Study - Recap of Contract/Business sponsor discussion
Thanks to everyone for your participation in our discussion on Aug 11 on the Shanghai Health Study.
The decisions/action items that I captured are as follows:

Decisions:

Stacy Methvin will sign contract amendment.
Harshad Topiwala will be the business sponsor.

Actions:

Nancy will brief Stacy and Harshad.
Patsy will notify Nancy when contract amendment is ready for signature.
Nancy will take contract to Stacy for signature.
Patsy will set up conference call to brief Stacy, Bill, and Harshad.

Regards,

Patsy

Patsy Clegg
Product Steward
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 **Fax:** 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Shanghai Health Study

- A project in Shanghai to study the effects of benzene exposure on the blood
- Principle Investigators: Dr. Richard Irons, University of Colorado
Dr. Otto Wong, Applied Health Sciences
- The \$21MM study is being funded by the Benzene Health Research Consortium which includes BP, ChevronTexaco, ConocoPhillips, ExxonMobil, Shell Chemical Company LP
- A clinical research lab has been built, equipped, and staffed on the campus of the School of Medicine at Fudan University in Shanghai. The lab will be gifted to the university.
- 26 area Shanghai hospitals are referring hematopoietic (blood and blood forming organs) related diseases to the study
- To date, just over 100 AML (acute myelogenous leukemia) and NHL (non-Hodgkin's lymphoma) cases have been referred.
- An independent Scientific Review Panel and an Ethics Review Panel have reviewed protocols and study progress.
- Shell is currently chairing the Oversight and Budget committees.
- The study is expected to conclude in 2007/8.